AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
-4.26%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$248M
AUM Growth
+$248M
(-30%)
Cap. Flow
-$66M
Cap. Flow
% of AUM
-26.6%
Top 10 Holdings %
Top 10 Hldgs %
65.48%
Holding
54
New
8
Increased
11
Reduced
3
Closed
19
Top Buys
| 1 |
Arcellx
ACLX
|
$17.6M |
| 2 |
Merus
MRUS
|
$16.1M |
| 3 |
Nuvalent
NUVL
|
$14.8M |
| 4 |
Soleno Therapeutics
SLNO
|
$9.89M |
| 5 |
Janux Therapeutics
JANX
|
$8.73M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$82M |
| 2 |
Novo Nordisk
NVO
|
$46.6M |
| 3 |
Viking Therapeutics
VKTX
|
$17.8M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$8.79M |
| 5 |
Axsome Therapeutics
AXSM
|
$7.89M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLRN
51
DELISTED
ACELYRIN
SLRN
| – | – |
-93,114
| Closed | -$459K |
|
52
Summit Therapeutics
SMMT
$17.5B
| – | – |
-14,512
| Closed | -$318K |
|
53
Syndax Pharmaceuticals
SNDX
$1.37B
| – | – |
-48,263
| Closed | -$929K |
|
|
54
Vertex Pharmaceuticals
VRTX
$101B
| – | – |
-18,900
| Closed | -$8.79M |
|